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A population-based prevalence sample of 355 resi-
dents of Cache County, Utah, who were diagnosed
with dementia, was rated on the Neuropsychiatric
Inventory (NPI). Of the 355 residents, 119 had
no neuropsychiatric symptoms at baseline and
were, consequently, at risk for incident mental
and behavioral disturbances. The NPI was read-
ministered approximately 18 months later to 61
surviving participants. Sixty-nine percent devel-
oped at least one mental or behavioral symptom.
Delusions were most common (28%), followed by
apathy (21%), and aberrant motor behavior
(21%). When this incidence rate of 69% was com-
bined with a previously estimated prevalence rate
of 61%, the cumulative 18-month prevalence ap-
proached 90%. These results argue for a routine
assessment of psychiatric disturbances in all pa-
tients with dementia, even among those who have
never experienced symptoms of mental or behav-
ioral disturbances.
(The Journal of Neuropsychiatry and Clinical
Neurosciences 2003; 15:340–345)
Among the elderly, dementing illnesses and theirconsequences are pressing concerns. Alzheimer’s
disease (AD) is the most common cause of dementia in
elderly patients, accounting for 50%–65% of cases.1,2
Vascular dementia (10%–15%) is probably the second
most common, and Dementia with Lewy Bodies (15%–
25%) is likely the third.1,2 Most dementias are irrevers-
ible and progressive, causing global cognitive and func-
tional decline and, ultimately, death. Mental and
behavioral disturbances, such as delusions, hallucina-
tions, depression, or agitation typically occur, causing
additional burden and suffering for patients and their
caregivers. According to estimates from clinical sam-
ples, as many as 70%–90% of patients with dementia
experience at least one mental or behavioral disturbance
during the course of their illness.3–7 Such psychiatric dis-
turbances are closely associated with impairment in
quality of life and caregiver distress.4,8–10 This associa-
tion may exceed that of the cognitive and functional
symptoms of dementia.11 Psychiatric disturbances are
also associated with more rapid cognitive decline, ear-
lier nursing home placement, and increased cost of
care.7,8,12
Two large population-based studies have estimated
the prevalence of mental and behavioral disturbances in
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dementia. The first study assessed 178 individuals with
AD in the United Kingdom.13–16 The following preva-
lence since the onset of illness was reported: apathy
(41%), major depression (24%), agitation/aggression
(20%), wandering (19%), hallucinations (17%), delusions
(16%), and mania (3.5%). More recently, the Cache
County study used the Neuropsychiatric Inventory
(NPI)17 to assess the prevalence of 10 mental and behav-
ioral disturbances in a cohort of 329 individuals with
dementias of various etiologies.6 Sixty-one percent of
participants experienced at least one disturbance in the
month prior to interview. In order of decreasing fre-
quency, the following disturbances were reported: apa-
thy (27%), depression (24%), agitation/aggression
(24%), irritability (20%), delusions (19%), anxiety (17%),
aberrant motor behavior (14%), hallucinations (14%),
disinhibition (9%), and elation (1%).
In the general population of persons with dementia,
less is known about the incidence of mental and behav-
ioral disturbances. One study estimated the incidence of
major depression in AD patients in two large commu-
nity-dwelling convenience series. Findings revealed a
0%, 3-year incidence in one series and a 1.3%, 2-year
incidence in the other.18 No population-based studies to
date have assessed the incidence of mental or behavioral
disturbances in dementia. Population-based studies of
incidence are important, as they avoid referral biases
inherent in studies from clinical samples, which would
tend to overestimate incidence. This study reports find-
ings on the incidence of mental and behavioral distur-
bances among participants with dementia whowere fol-
lowed in the Cache County study.
METHODS
Sampling and Screening
The methods of the Cache County study are reported in
detail elsewhere.6,19 We contacted all permanent resi-
dents of Cache County, Utah, who were 65 years old or
older in January 1995 (N  5,677) and enrolled 5,092
residents (90%) who were screened for dementia with
the Modified Mini-Mental State Examination.20 Individ-
uals who could not participate directly were character-
ized using the Informant Questionnaire on Cognitive
Decline in the Elderly21 that was administered by a
knowledgeable informant. Individuals whose screening
scores suggested possible cognitive impairment were
studied further with the Dementia Questionnaire.22 The
Dementia Questionnaire was also used to assess a
weighted, stratified probability sample of the total
population, irrespective of the above screening results.
The latter probability subsample, along with all other
participants with a Dementia Questionnaire rating of 4
(suspected dementia) or 5 (probable dementia), under-
went a comprehensive clinical assessment performed by
a research nurse and a trained psychometrician. This as-
sessment was conducted in the presence of a collateral
informant at the subject’s place of residence (including
nursing homes). The informant was a spouse, close rela-
tive, or other person whom the subject identified as
knowledgeable of his or her memory and daily func-
tioning. The evaluation consisted of a medical and cog-
nitive history, mental state and standardized neurolog-
ical exams, a brief physical evaluation, and a 1-hour
neuropsychological battery, including the Mini-Mental
State Examination (MMSE).23 The NPI17 was adminis-
tered by either the nurse or the psychometrician.
The study was approved by the institutional review
boards of Duke University Medical Center, the Johns
Hopkins University School of Public Health, and Utah
State University. All study participants, or their next of
kin, signed an informed consent document after a com-
plete description of the study for each stage of the
screening and assessment was given.
Procedure
After screening and careful case ascertainment, we iden-
tified 355 participants with dementia. Of these, 119 had
a baseline NPI score of 0 (no symptoms in any domain).
These are the populations of interest here, as they were
at risk for the incidence of NPI-ascertained disturbances
at follow-up examinations conducted approximately 18
months later (mean interval to follow-up 17.1, SD 
4.2). Therefore, NPI data were obtained on all of the re-
maining 61 (51%). Thirty-three (27%) died in the interim,
and one (0.8%) moved away from the area. Twenty-two
(18%) had no collateral informant available for NPI
questions, and two (1.6%) refused the NPI or discontin-
ued early. Stated otherwise, NPI follow-upwas obtained
on 61/85 (72%) of those who were alive and available
for investigation. The same informant was used for the
18-month follow-up in 75.8% of the cases.
Similar to the methods we used to estimate psychi-
atric prevalence,6 we reviewed data from these 18-
month follow-up evaluations in order to classify study
participants into distinct clinical diagnostic categories.
These assignments were made at initial diagnostic con-
ferences that included the staff who conducted the eval-
uation and a geriatric psychiatrist (D.C.S, M.S., J.C.S.B.,
or C.G.L.). A Clinical Dementia Rating (CDR) level was
assigned to each participant during this time. The CDR
is a standardized global rating of dementia severity
based on all available information about a patient.24
Cases were then reviewed by a panel of experts for as-
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signment of final diagnosis. The panel included three
geriatric psychiatrists, a board-certified neurologist, a
senior neuropsychologist, and a cognitive neuroscien-
tist.
Assessment of Mental and Behavioral Disturbances
The reliability and validity of the NPI have been estab-
lished17 and have been used in a variety of studies, in-
cluding our study of the prevalence of mental and be-
havioral disturbances in Cache County.6
The NPI version assesses 10 categories of mental and
behavioral disturbances that occur in dementia: delu-
sions; hallucinations; agitation; depression; anxiety; ela-
tion; apathy; disinhibition; irritability; and aberrant mo-
tor behavior, such as wandering or pacing. The
instrument examines whether symptoms have occurred
over a period of onemonth from the time the assessment
is conducted. Each operationally defined disturbance is
ascertained by a trained examiner through a structured
interview with the caregiver. Within each domain, the
NPI includes a screening question. If the screening item
is answered in the negative, the rater is instructed to
move to the next domain. Otherwise, the rater asks the
informant a series of individual questions describing be-
havior reflective of disturbance in that domain. The in-
formant is then asked about the frequency of symptoms
in the domain on a 4-point scale from 1 (occasionally:
less than once a week) to 4 (very frequent: more than
once a day). The informant is also asked to rate the se-
verity (disruptiveness, burden) of the behavior on a 3-
point scale (mild, moderate, or severe). By multiplying
the severity and frequency scores, the NPI yields a do-
main rating with a range from 0 to 12.
Analysis
Our primary goal was to determine the incidence of dis-
turbance in each NPI domain. Baseline demographics
(e.g., age, sex, education) and clinical variables (e.g.,
MMSE score, dementia duration, percentage with AD
diagnosis, CDR level) of the 61 participants with com-
pleted NPIs at follow-up and the 58 participantswithout
completed NPIs at follow-up were compared in order
to assess obvious bias in loss to follow-up. Similarly,
baseline variables were compared for those with an NPI
score of 0 (no disturbances) at 18-month follow-up ver-
sus those with an NPI score of 1 or greater. We deter-
mined the proportion of participants who had symp-
toms in at least one domain at 18-month follow-up. We
further determined the proportion with symptoms in
each of the 10 NPI domains. A mean severity score was
estimated for those with symptoms in any given do-
main.
RESULTS
Table 1 compares demographic and clinical character-
istics of the 61 participants who had a baselineNPI score
of 0 and completed an 18-month follow-up evaluation,
versus the 58 participants who did not. Those who did
not complete follow-up NPIs showed a trend toward a
longer duration of dementia (p  .06), but the two
groups were otherwise similar.
Of the 61 participants with follow-up NPI data, 42
(68.9%) exhibited at least one NPI-ascertained distur-
bance. Table 2 compares the baseline characteristics of the
19 participants who did not exhibit anyNPI-assesseddis-
turbance, as compared with the 42 who did. Those with
incident NPI-assessed disturbances tended to be older,
although this distinction did not reach statistical signifi-
cance (p  .08). Of the 42 with an NPI disturbance at
follow-up, 27 (64.3%) were diagnosed with AD, 1 (2.4%)
with vascular dementia, 6 (14.3%) with a mixed AD and
vascular dementia and 8 (19.0)% with other dementias:
dementia of undetermined etiology (2), neuropsychiatric
disorder (1), Parkinson’s disease (1), amyotrophic lateral
sclerosis with dementia (1), normal-pressure hydroceph-
alus (1), dementia with Lewy bodies (1), and dementia
lacking distinctive histology on autopsy (1).
We also estimated the incidence of each individual
NPI disturbance and themeanNPI severity score of sub-
jects who were symptomatic in each domain. Table 3
shows these results. Incidence of delusions was highest,
followed by apathy, aberrant motor behavior, and irri-
tability. Incidence was lowest for elation, followed by
disinhibition. All other domains had an 18-month in-
cidence of at least 14.8%. Among those with symptoms
in any given domain, the mean severity on the NPI 12-
point domain scale was highest for agitation/aggres-
sion (6.4), followed by apathy (5.6) and depression
(4.7). Lowest mean severity was noted for hallucina-
tions (2.9) and disinhibition (2.0). Clinical significance
of a psychiatric disturbance has been defined as a do-
main score of 4 or greater {personal communication,
Clinical Antipsychotic Trials of Intervention Effective-
ness (CATIE) study}.
DISCUSSION
We report findings on the incidence of mental and be-
havioral disturbance in a population-based panel of el-
derly individuals with dementia who had been free
from such comorbid symptoms approximately 18
months earlier. To our knowledge, no other study has
reported similar estimates from a population sample.
We found that 69% of participants developed at least
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TABLE 1. Baseline demographic and clinical characteristics of participants with and without completed NPI at 18-month follow-up
Completed NPI not
Available at F/U (n 58)
Completed NPI
Available at F/U (n 61)
Characteristic Mean SD Mean SD t test (df) p
Age (yrs.) 85.7 6.4 83.7 7.1 1.61(117) 0.11
MMSE score 16.3 6.9 18.0 6.9 1.34(117) 0.18
Education (yrs.) 11.7 3.5 12.6 3.2 1.47(117) 0.15
Dementia duration (yrs.) 4.4 3.3 3.4 2.4 1.90(117) 0.06
Characteristic
Completed NPI not
Available at F/U (n 58),
n(%)
Completed NPI Available
at F/U (n 61),
n(%) Chi square (df) p
Male gender 23(39.7) 27(44.3) 0.104(1) 0.75
% AD diagnosis 33(56.9) 41(67.2) 1.35(1) 0.25
CDR level
0.5
1
2
3-5
3(5.2)
20(34.5)
15(25.9)
20(34.5)
4(6.6)
31(50.8)
14(23.0)
12(19.7)
4.48(3) 0.21
TABLE 2 Baseline demographic and clinical characteristics of participants with 18-month follow-up NPI 0 and NPI 1 or greater
No NPI Disturbance
at F/U (n 19)
Any One NPI
Disturbance at F/U
(n 42)
Characteristic Mean SD Mean SD t test (df) p
Age (yrs.) 82.5 7.5 86.0 6.9 1.79(59) 0.08
MMSE score 17.6 6.8 17.8 7.2 0.08(55) 0.94
Education (yrs.) 12.7 3.6 12.4 3.1 0.33(59) 0.74
Dementia duration (yrs.) 4.5 2.3 4.9 2.7 0.56(59) 0.58
Characteristic
No NPI Disturbance
at F/U (n19)
n(%)
NPI Disturbance at
F/U (n 42)
n(%) Chi square (df) p
Male gender 9(47.4) 18(42.9) 0.00(1) 0.96
% AD diagnosis 14(73.7) 27(64.3) 0.52(1) 0.47
CDR level
0.5
1
2
3–5
3(15.8)
9(47.4)
5(26.3)
2(10.5)
1(2.4)
22(52.4)
9(21.4)
10(23.8)
4.96(3) 0.18
TABLE 3. Incidence of Individual NPI disturbances at 18-month
F/U and mean severity score among those with
symptoms in each disturbance
Domain
N (%) in
Domain With
NPI  0
(n 61)
Mean Severity Score
(SD) Among Those
With Symptoms in
Domain
Delusions 17 (27.9) 4.1 (3.6)
Apathy 13 (21.3) 5.6 (3.6)
Aberrant Motor Behavior 13 (21.3) 3.7 (2.5)
Irritability 12 (19.7) 3.8 (4.0)
Depression 11 (18.0) 4.7 (3.2)
Hallucinations 10 (16.4) 2.9 (1.3)
Agitation/Aggression 10 (16.4) 6.4 (3.8)
Anxiety 9 (14.8) 3.6 (2.6)
Disinhibition 6 (9.8) 2.0 (0.9)
Elation 0 (0) N/A
onemental or behavioral symptomduring the 18-month
interval. For eight of the 10 NPI domains assessed,
symptoms occurred in at least 15% of all subjects. Ela-
tion was the only symptom to have a 0% incidence, con-
sistent with other findings of the relative rarity of manic
and euphoric symptoms in dementia.6,15,25 These esti-
mates likely underestimate true incidence, as we only
inquired about symptoms occurring during the month
prior to assessment. It is likely that some participants
developed psychiatric symptoms during the 18-month
interval that resolved prior to reassessment, either spon-
taneously or after treatment.
Additionally, we observed that 61% of participants
who were initially identified with dementia had one or
more NPI-ascertained mental or behavioral symptoms.
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Those subjects were not studied here, but combining
their original prevalence of 61% with the 69% showing
incident, symptoms indicate that the cumulative prev-
alence of mental or behavioral disturbances in dementia
during 18 months may be as much as 88.6%.
Incident symptom severity was highest among sub-
jects who developed agitation/aggression, depression,
or apathy. Such symptoms are among the most distress-
ing to both patients and caregivers and typically require
a multidimensional treatment plan involving pharma-
cotherapy and/or environmental modification.8,26
Prompt diagnosis and intervention may alleviate the
need for placement in an assisted living or nursing fa-
cility. Disinhibition and hallucinations were of mildest
severity when they occurred. Often, these latter symp-
toms respond best to reassurance and redirection.7,8
Several limitations of our study are worthy of discus-
sion. First, as previously mentioned, we studied a popu-
lation that may not be fully representative. The Cache
County population is older and less ethnically diverse
than the rest of the United States, and it has higher rates
of religious affiliation and lower rates of alcoholism and
substance abuse than elsewhere.19 Second, the principal
method of assessing mental and behavioral distur-
bances, the NPI, relied on informants rather than the
direct examination of participants. Third, there was a
fairly wide range in the time that elapsed between base-
line visits and “18-month” follow-up visits. This limits
our ability to draw precise estimates about incidence,
but does not compromise our study’s central finding of
a high incidence of psychiatric disturbances in subjects
who were previously assessed as symptom-free. Finally,
the present sample was small, especially as compared
with our prevalence study. Nearly one-half of the origi-
nal panel of symptom-free participants did not have a
follow-up NPI. Most losses to follow-up were due to
intercurrent death or lack of a collateral informant. NPI
data were obtained on three-quarters of those who were
alive and available. Those subjects who did not com-
plete the follow-up NPIs showed a trend toward a
longer duration of dementia but otherwise had similar
baseline characteristics.
These findings add to the growing body of evidence
for the high occurrence of comorbid psychiatric symp-
toms in dementia and show that even patients who are
asymptomatic at a given time are still at very high risk
for developing psychiatric disturbances later. Psychiat-
ric comorbidity in dementia is often complex to treat
and typically requires a rigorous assessment and so-
phisticated treatment plan. Management may involve
behavioral and/or pharmacological interventions. Suc-
cessful strategies often involve some combination of the
two.7,8,26 Behavioral treatments may include modifying
the environment, altering the caregiving approach, and
providing structured activities. Such techniques alone
may be useful with symptoms of milder severity or
when psychotropic use is contraindicated.7,8
Two large placebo-controlled studies have docu-
mented the benefits of atypical neuroleptics in the treat-
ment of behavioral symptoms in AD.27,28 Placebo-con-
trolled studies have also demonstrated the benefits of
carbamazepine29 and divalproex sodium30 for agitation
and aggression. Preliminary data from another placebo-
controlled trial demonstrate the effectiveness of sertra-
line in the treatment of depression in AD.31 Recent data
also suggest that cholinesterase inhibitors, which are ap-
proved by the Food and Drug Administration (FDA) to
treat the cognitive symptoms of AD, may also provide
behavioral benefits.32,33 The potential for effective treat-
ment options and the high incidence rates observed in
our study make early evaluation of psychiatric distur-
bances in dementia a vital necessity.
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References
1. Bolla LR, Filley CM, Palmer RM: Office diagnosis of the four
major types of dementia. Geriatrics 2000; 55:34–46
2. Small GW, Rabins PV, Barry PP, et al: Diagnosis and treatment
of Alzheimer’s disease and related disorders: consensus state-
ment of the American Association for Geriatric Psychiatry, the
Alzheimer’s Association, and the American Geriatrics Society.
JAMA 1997; 278:1363–1371
3. Tariot PN, Mack JL, Patterson MB, et al: The Behavior Rating
Scale for Dementia of the Consortium to Establish a Registry for
Alzheimer’s Disease. Am J Psychiatry 1995; 152:1349–1357
4. Teri L, Logsdon RG, Peskind E, et al: Treatment of agitation in
AD: a randomized, placebo-controlled clinical trial. Neurology
2000; 55:1271–1278
5. Rao V, Lyketsos CG: Delusions in Alzheimer’s disease: a review.
J Neuropsychiatry Clin Neurosci 1998; 10:373–382
6. Lyketsos C, Steinberg M, Tschanz J, et al: Mental and behavioral
disturbances in dementia: findings from the Cache County
Study on Memory in Aging. Am J Psychiatry 2000; 157:708–714
7. Lyketsos C, Steele C, Steinberg M: Behavioral disturbances in
dementia, in Reichel’s Care of the Elderly. Edited by Gallo JJ,
Busby-Whitehead J, Rabins PV, Silliman R, Murphy J. Baltimore,
Williams & Wilkins, 1999, pp 214–218
8. Rabins PV, Lyketsos CG, Steele CD: Practical Dementia Care.
New York, Oxford University Press, 1999
9. Lyketsos CG, Breitner JCS, Rabins PV: An evidence-based pro-
posal for the classification of neuropsychiatric disturbance in
J Neuropsychiatry Clin Neurosci 15:3, Summer 2003 345
STEINBERG et al.
Alzheimer’s disease. Int J Geriatr Psychiatry 2001; 16:1037–
1042
10. Deimling GT, Bass DM: Symptoms ofmental impairment among
elderly adults and their effects on family caregivers. J Gerontol-
ogy 1986; 41:778–784
11. Gonzales-Salvador T, Arango C, Lyketsos CG, et al: The stress
and psychological morbidity of the Alzheimer patient caregiver.
Int J Geriat Psychiatry 1999; 14:701–710
12. Teri L, Hughes JP, Larson EB: Cognitive deterioration in Alzhei-
mer’s disease: behavioral and health factors. J Gerontol B: Psy-
chol Sci 1990; 45:P58–P63
13. Burns A, Jacoby R, Levy R: Psychiatric phenomena in Alzhei-
mer’s disease I: disorders of thought content. Br J Psychiatry
1990; 157:72–76
14. Burns A, Jacoby R, Levy R: Psychiatric phenomena in Alzhei-
mer’s disease II: disorders of perception. Br J Psychiatry 1990;
157:76–81
15. Burns A, Jacoby R, Levy R: Psychiatric phenomena in Alzhei-
mer’s disease III: disorders of mood. Br J Psychiatry 1990;
157:81–86
16. Burns A, Jacoby R, Levy R: Psychiatric phenomena in Alzhei-
mer’s disease IV: disorders of behavior. Br J Psychiatry 1990;
157:86–94
17. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric In-
ventory: comprehensive assessment of psychopathology in de-
mentia. Neurology 1994; 44:2308–2314
18. Weiner M, Edland S, Luszczynska H: Prevalence and incidence
of major depression in Alzheimer’s disease. Am J Psychiatry
1994; 151:1006–1009
19. Breitner JCS, Wyse BW, Anthony JC, et al: APOE-epsilon 4 count
predicts age when prevalence of Alzheimer’s disease increases-
then declines: the Cache County Study. Neurology 1999; 52:321–
331
20. Teng EL, Chui HC: The Modified Mini-Mental State (3MS) ex-
amination. J Clin Psychiatry 1987; 48:314–318
21. Jorm AF: A short form of the Informant Questionnaire on Cog-
nitive Decline in the Elderly (IQCODE): development and cross-
validation. Psychol 1994; 24:145–153
22. Silverman JM, Breitner JCS, Mohs RC, et al: Reliability of the
family history method in genetic studies of Alzheimer’s disease
and related dementias. Am J Psychiatry 1986; 143:1279–1282
23. Folstein M, Folstein S, McHugh P: “Mini-Mental State”: a prac-
tical method of grading the cognitive state of patients for clini-
cians. J Psychiatr Res 975; 12:189–198
24. Morris J: Clinical Dementia Rating Scale. St. Louis, Washington
University, 1994
25. Lyketsos CG, Corazzini K, Steele C: Mania in Alzheimer’s dis-
ease. J Neuropsychiatry Clin Neurosci 1998; 10:440–447
26. Leroi I, Steele C, Lyketsos CG: The care of patients with demen-
tia. Reviews in Clinical Gerontology 1999; 9:235–255
27. Katz IR, Jeste DV, Mintzer JE, et al: Comparison of risperidone
and placebo for psychosis and behavioral disturbances associ-
ated with dementia: a randomized, double-blind trial. J Clin Psy-
chiatry 1999; 60:107–115
28. Street J, Clark S, Gannon K, et al: Olanzapine treatment of psy-
chotic and behavioral symptoms in patients with Alzheimer’s
disease in nursing care facilities: a double-blind randomizedpla-
cebo-controlled trial. Arch Gen Psychiatry 2000; 57:968–976
29. Tariot PN, Erb R, Podgorski CA, et al: Efficacy and tolerability
of carbamazepine for agitation and aggression in dementia. Am
J Psychiatry 1998; 155:54–61
30. PorsteinssonAP, Tariot PN, Erb R, et al: Placebo-controlledstudy
of divalproex sodium for agitation in dementia. Am J Geriatr
Psychiatry 2001; 9:58–66
31. Lyketsos CG, Sheppard J, Steele C, et al: A randomized, placebo-
controlled, double-blind clinical trial of sertraline in the treat-
ment of depression complicating Alzheimer’s disease: initial re-
sults from the Depression in Alzheimer’s Disease Study
(DIADS). Am J Psychiatry 2000; 57:968–976
32. Cummings JL, Arnand R, Koumaris B, et al: Rivastigmine pro-
vides behavioral benefits to Alzheimer’s disease patients resid-
ing in a nursing home: findings from a 26-week trial. Neurology
2000; 54(suppl 3):A468
33. Tariot PN, Solomon PR, Morris JC, et al: A 5-month randomized,
placebo-controlled trial of galantamine in AD. Neurology 2000;
15:586–593
